[Gene therapy in diabetic foot]

Area of Science:

• Molecular Biology
• Regenerative Medicine
• Wound Healing Research

Background:

• Gene therapy offers novel therapeutic strategies for chronic wound management.
• Current approaches involve growth factor synthesis, ex-vivo cell transfection, and in-vivo gene delivery.
• Diabetic foot ulcers represent a significant clinical challenge with limited effective treatments.

Purpose of the Study:

• To review gene therapy concepts applicable to chronic wound treatment.
• To evaluate the clinical efficacy of gene therapy for diabetic foot ulcers.
• To assess the impact of recombinant human platelet-derived growth factor-BB (PDGF-BB) on wound healing.

Main Methods:

• Review of gene therapy techniques including recombinant protein synthesis, ex-vivo cell modification, and in-vivo gene transfer (gene gun, liposomes, viral vectors).
• Analysis of clinical studies focusing on gene therapy for chronic wounds, specifically diabetic foot ulcers.
• Meta-analysis of data concerning the local application of human recombinant PDGF-BB.

Main Results:

• Clinical evidence for gene therapy in chronic wounds is primarily limited to diabetic foot ulcers.
• The local application of human recombinant PDGF-BB demonstrated a statistically significant, albeit low, effect on healing.
• A 10-15% increase in healing rates for neuropathic diabetic ulcers was observed within 20 weeks of PDGF-BB treatment.

Conclusions:

• Gene therapy presents a promising avenue for treating chronic wounds, particularly diabetic foot ulcers.
• Recombinant PDGF-BB shows a modest but significant benefit in promoting the healing of neuropathic diabetic ulcers.
• Further research into advanced gene therapy modalities is warranted to optimize chronic wound treatment outcomes.